AbCellera Investor Presentation Deck

CORPORATE OVERVIEW COPYRIGHT © ABCELLERA 14 PORTFOLIO DIVERSIFIED ACROSS MODALITIES, PARTNER SIZE, AND DEAL TYPE. 69** 6* partner-initiated partner-initiated discovery program starts** co-development program starts** 41 partners 9 molecules in the clinic * As of December 31, 2022 ** With downstream participation 12* pre-partnered program starts (TCE, GPCR, ion channel, Covid-19) 2 authorized antibody therapies REGENERON gsk NOVARTIS GILEAD Ablynx A SANOFI COMPANY EMPIRICO ANART SANHIARSH THE AUTRES LLOW ANY Autolus TACHYON Lilly له EVEREST MEDICINES SANOFI biosciences Rallybio angios Lyell teva moderna EQR™ REMAKING MEDICINE Pfizer KODIAK DENALI X Invetx MERCK BILL & MELINDA GATES foundation

View entire presentation